D. Tsushima

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

J. Chabot, P. Stevens, Yuehua Mao, 2013, Cancer Chemotherapy and Pharmacology.

Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature

R. Fine, R. Moss, A. Gulati, 2012, Oncology.

Capecitabine (Xeloda®) and Temozolomide (Temodar®) as a Potential Therapy for Pituitary Tumors

R. Fine, D. Tsushima, T. Golato, 2017 .

Prospective phase II trial of GTX in metastatic pancreatic cancer: Laboratory and clinical studies.

J. Chabot, R. Fine, J. Allendorf, 2013 .

Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.

J. Bruce, J. Chabot, R. Fine, 2014 .

Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature

R. Fine, R. Moss, A. Gulati, 2012, Oncology.